在雾中肺炎和肠炎华盛顿大学ppt课件.pptVIP

A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting;Adult Treatment Panel III (ATP III) Guidelines;National Cholesterol Education Program Reports;New Features of ATP III;New Features of ATP III (continued);New Features of ATP III (continued);New Features of ATP III (continued);Cost-Effectiveness Issues;Categories of Risk Factors;Life-Habit Risk Factors;Emerging Risk Factors;Risk Assessment;;Diabetes;CHD Risk Equivalents;Diabetes as a CHD Risk Equivalent;CHD Risk Equivalents;Risk Category CHD and CHD riskequivalents Multiple (2+) risk factors Zero to one risk factor;ATP III Lipid and Lipoprotein Classification ;ATP III Lipid and Lipoprotein Classification (continued);ATP III Lipid and Lipoprotein Classification (continued);ATP III GuidelinesGoals and TreatmentOverview;Primary Prevention With LDL-Lowering Therapy;LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories;LDL Cholesterol Goal and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Patients with CHD and CHD Risk Equivalents (10-Year Risk 20%);LDL Cholesterol Goal and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Patients with Multiple Risk Factors (10-Year Risk ?20%);LDL Cholesterol Goal and Cutpoints for Therapeutic Lifestyle Changes (TLC) and DrugTherapy in Patients with 0–1 Risk Factor;LDL-Lowering Therapy in Patients With CHD and CHD Risk Equivalents;LDL-Lowering Therapy in Patients With CHD and CHD Risk Equivalents;LDL-Lowering Therapy in Patients With CHD and CHD Risk Equivalents;LDL-Lowering Therapy in Patients With Multiple (2+) Risk Factors and 10-Year Risk ?20%;LDL-Lowering Therapy in Patients With Multiple (2+) Risk Factors and 10-Year Risk ?20%;LDL-Lowering Therapy in Patients With 0–1 Risk Factor;LDL-Lowering Therapy in Patients With 0–1 Risk Factor and LDL-Cholesterol 160-189 mg/dL (after lifestyle therapies);;;